SCHEMBL4719978

SCHEMBL4719978

CC(C)(C)OC(=O)N(CCC=CC(=O)O)Cc1ccccc1Br

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR52 Q9Y2T5 1/20 0.41
SSTR4 P31391 1/20 0.41
TSHR P16473 2/20 0.38
CTSS P25774 2/20 0.38
CTSK P43235 1/20 0.38
NPSR1 Q6W5P4 1/20 0.37
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
NCOR2 Q9Y618 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
NFKB1 P19838 1/20 0.36
CYP2C19 P33261 1/20 0.36
HSD17B10 Q99714 1/20 0.36
CHRM2 P08172 2/20 0.35
CHRM1 P11229 2/20 0.35
CHRM3 P20309 2/20 0.35
LMNA P02545 1/20 0.35
BLM P54132 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4719975 1.00 GPR52 (0.41) GPR52SSTR4TSHRCTSSCTSK
SCHEMBL4716435 0.88 SSTR4 (0.39) GPR52SSTR4CTSSCTSKHDAC3
SCHEMBL4716445 0.88 SSTR4 (0.39) GPR52SSTR4CTSSCTSKHDAC3
SCHEMBL4715976 0.87 SSTR4 (0.43) GPR52SSTR4RIPK1
SCHEMBL4715979 0.87 SSTR4 (0.43) GPR52SSTR4RIPK1
SCHEMBL4717219 0.86 SSTR4 (0.38) GPR52SSTR4TSHRHSD17B10LMNA
SCHEMBL7428367 0.83 SSTR4 (0.40) SSTR4RIPK1
SCHEMBL4762111 0.83 ITGA4 (0.39) SSTR4LMNA
SCHEMBL4718059 0.79 SSTR4 (0.50) SSTR4TSHRCTSSCTSKNPSR1
SCHEMBL13168302 0.79 SSTR4 (0.45) SSTR4TSHRCTSSCTSKHDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1216230-B1 FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS AMGEN INC (US) 2008-04-23 EP disclosed
US-6514964-B1 Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors AMGEN INC. 2003-02-04 US disclosed
EP-1216230-A2 FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS Amgen Inc. (US) 2002-06-26 EP disclosed
WO-2001023357-A2 FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS AMGEN INC. (US) 2001-04-05 WO disclosed